Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Study of Alefacept in Adolescents With Moderate to Severe Psoriasis
2008-005830-63Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Apr 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alefacept in plaque psoriasis and psoriasis, sponsored by Astellas Pharma. Primary endpoints: Safety of alefacept in adolescent subjects and Pharmacokinetics of alefacept. Started Apr 2009; status: terminated.
02
Drugs
alefacept
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2008-005830-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005830-63.